Conditions: Parkinson Disease
Keywords: Parkinson Disease BIA 9-1067
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 52
Healthy volunteers: yes

Brief summary:
To investigate the effect of BIA 9-1067 in steady-state conditions on the levodopa pharmacokinetics

Detailed description:
Single centre, randomized, double-blind, gender-balanced, placebo-controlled study in 4 groups of healthy subjects

Arms:
arm 1: 5 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28 arm 2: Placebo once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28. arm 3: 15 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28 arm 4: 30 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28

Interventions: intervention 1: BIA 9-1067 intervention 2: Placebo intervention 3: levodopa/carbidopa intervention 4: levodopa/benserazide
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None intervention 4: None

Protocol document: